ArticleBMC infectious diseases2025
Epidemiological and clinical characteristics of hospitalized pediatric patients with Mycoplasma pneumoniae pneumonia before and after the COVID-19 pandemic in China: a retrospective multicenter study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Nonlinear age-season dynamics and macrolide resistance of Mycoplasma pneumoniae: a large pediatric cohort study during the post-pandemic resurgence.BMC infectious diseases · 2026Article
- [Trends, predictions, and etiological characteristics of the incidence and mortality of lower respiratory infections among children under 14 years in China from 1990 to 2021].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- DNA methylation changes in thyroid cancer patients infected with SARS-CoV-2.Updates in surgery · 2026Article
- Impact of COVID-19 on the epidemiological features of mycoplasma pneumoniae infection in children with community-acquired pneumonia in Ganzhou, China.Frontiers in immunology · 2026Article
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
- Risk factors for hospitalization in pediatric patients with human adenovirus infection and changes in epidemiological and clinical characteristics before and after the COVID-19 pandemic in China: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Doxycycline vs levofloxacin for macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a real-world study from China.Italian journal of pediatrics · 2025Observational
- Mycoplasma pneumoniae in hospitalised children in the post-COVID era: clinical outcomes from a Turkish multicenter cohort.European journal of pediatrics · 2025Article
- An mRNA Vaccine Targeting the C-Terminal Region of P1 Protein Induces an Immune Response and Protects AgainstInternational journal of molecular sciences · 2025Article
- Epidemiological association of the COVID-19 pandemic onBMJ open · 2025Article
- Re-emergence of Mycoplasma pneumoniae before and after COVID-19 pandemic in Germany.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn China many respiratory pathogens stayed low activities amid the COVID-19 pandemic due to strict measures and controls. We here aimed to study the epidemiological and clinical characteristics of pediatric inpatients with Mycoplasma pneumoniae pneumonia (MPP) after the mandatory COVID-19 restrictions were lifted, in comparison to those before the COVID-19 pandemic.
methodsWe here included 4,296 pediatric patients with MPP, hospitalized by two medical centers in Jiangsu Province, China, from January 2015 to March 2024. Patients were divided into the pre-COVID (n = 1,662) and post-COVID (n = 2,634) groups. Their baseline characteristics, laboratory test results and radiological patterns were separately assessed and compared between the two groups to determine the substantial changes in the disease profile of MPP after the COVID-19 pandemic.
resultsEpidemiological results suggested a higher annual incidence of MPP after the COVID-19 pandemic when the outbreak reached a peak in October, two months delayed in seasonality compared to that in the pre-COVID era. For pediatric patients with MPP, there was no difference in their median ages, gender ratios, and severe case percentages between the two groups, where most patients were younger than 14 years old. With significance, the post-COVID group had more occurrences of cough and expectoration and higher incidences of influenza A/B virus (IAV/IBV) co-infection than the pre-COVID group. Many hematological parameters and radiological features between the two groups displayed alteration, but comparatively there demonstrated no worsened severity in hospitalized children with MPP after COVID-19 pandemic. Concurrently, the post-COVID group was administered with fewer antibiotics but more corticosteroids for effective treatment than the pre-COVID group.
conclusionThrough the COVID-19 pandemic, the epidemiological and clinical characteristics of pediatric patients with MPP differed, but there was no evident change in the disease severity. After the COVID-19 pandemic, the increased incidence of IAV/IBV co-infection may contribute to the differences in clinical symptoms and hematological profiles, while the adding usage of corticosteroids might treat more effectively.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.